DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer.

ABSTRACT:

SUBMITTER: Li X 

PROVIDER: S-EPMC11976708 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature